These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

303 related items for PubMed ID: 20489419

  • 1. Strategies for the development of new PPAR agonists in diabetes.
    Cavender MA, Nicholls SJ, Lincoff AM.
    Eur J Cardiovasc Prev Rehabil; 2010 May; 17 Suppl 1():S32-7. PubMed ID: 20489419
    [Abstract] [Full Text] [Related]

  • 2. PPAR agonists and the metabolic syndrome.
    Staels B.
    Therapie; 2007 May; 62(4):319-26. PubMed ID: 17983557
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Glycemic control and cardiovascular mortality.
    Riddle MC.
    Curr Opin Endocrinol Diabetes Obes; 2011 Apr; 18(2):104-9. PubMed ID: 21522000
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Peroxisome proliferator activated receptor ligands for the treatment of insulin resistance.
    Patsouris D, Müller M, Kersten S.
    Curr Opin Investig Drugs; 2004 Oct; 5(10):1045-50. PubMed ID: 15535425
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. PPAR ligands: are they potential agents for cardiovascular disorders?
    Balakumar P, Rose M, Singh M.
    Pharmacology; 2007 Oct; 80(1):1-10. PubMed ID: 17496434
    [Abstract] [Full Text] [Related]

  • 9. Selective PPAR agonists for the treatment of type 2 diabetes.
    Nehlin JO, Mogensen JP, Petterson I, Jeppesen L, Fleckner J, Wulff EM, Sauerberg P.
    Ann N Y Acad Sci; 2006 May; 1067():448-53. PubMed ID: 16804025
    [Abstract] [Full Text] [Related]

  • 10. Statins and diabetes.
    Carmena R, Betteridge DJ.
    Semin Vasc Med; 2004 Nov; 4(4):321-32. PubMed ID: 15861314
    [Abstract] [Full Text] [Related]

  • 11. Role of the PPAR family of nuclear receptors in the regulation of metabolic and cardiovascular homeostasis: new approaches to therapy.
    Chinetti-Gbaguidi G, Fruchart JC, Staels B.
    Curr Opin Pharmacol; 2005 Apr; 5(2):177-83. PubMed ID: 15780828
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Drug Insight: mechanisms of action and therapeutic applications for agonists of peroxisome proliferator-activated receptors.
    Gervois P, Fruchart JC, Staels B.
    Nat Clin Pract Endocrinol Metab; 2007 Feb; 3(2):145-56. PubMed ID: 17237841
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Peroxisome proliferator-activated receptor (PPAR α/γ) agonists as a potential target to reduce cardiovascular risk in diabetes.
    Nicholls SJ, Uno K.
    Diab Vasc Dis Res; 2012 Apr; 9(2):89-94. PubMed ID: 22407927
    [Abstract] [Full Text] [Related]

  • 17. [Nuclear receptors PPAR as a drug target in metabolic disorders].
    Stolarczyk M, Gutman W, Derlacz RA.
    Postepy Biochem; 2011 Apr; 57(2):207-14. PubMed ID: 21913422
    [Abstract] [Full Text] [Related]

  • 18. Inflammation in diabetes mellitus: role of peroxisome proliferator-activated receptor-alpha and peroxisome proliferator-activated receptor-gamma agonists.
    Libby P, Plutzky J.
    Am J Cardiol; 2007 Feb 19; 99(4A):27B-40B. PubMed ID: 17307056
    [Abstract] [Full Text] [Related]

  • 19. [The role of PPARs and their isoforms in metabolic disorders related to insulin resistance and diabetes].
    Kravchenko NA, Iarmysh NV.
    Tsitol Genet; 2011 Feb 19; 45(3):68-78. PubMed ID: 21774406
    [Abstract] [Full Text] [Related]

  • 20. Evolution of peroxisome proliferator-activated receptor agonists.
    Chang F, Jaber LA, Berlie HD, O'Connell MB.
    Ann Pharmacother; 2007 Jun 19; 41(6):973-83. PubMed ID: 17519293
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.